TrialBritish journal of clinical pharmacology2011

The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.

Arne Ring et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.